GlassScriptPhysician profile
Jack Pieniazek
NPI 1164426870
$4,606.89
in general payments reported to CMS, 2019-2025
24 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,284 · 2020: $305 · 2022: $112 · 2023: $254 · 2024: $122 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $681.12 | 2019-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $623.14 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $474.48 | 2022-2025 | |
| Glaxosmithkline, LLC. | $396.36 | 2019-2020 | |
| Lilly USA, LLC | $356.33 | 2019-2024 | Mounjaro |
| Amarin Pharma, INC. | $343.24 | 2019-2020 | |
| Vertiflex, INC. | $245.27 | 2019 | |
| Allergan, INC. | $217.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $191.80 | 2019 | |
| Novo Nordisk INC | $172.60 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $125.00 | 2025 | Zoryve |
| Corcept Therapeutics | $96.81 | 2019 | |
| Pfizer INC. | $45.06 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $44.80 | 2019-2020 | |
| Abbott Laboratories | $40.69 | 2019-2020 | |
| Abbvie INC. | $31.19 | 2023 | |
| Philips North America LLC | $27.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.25 | 2019 | |
| Currax Pharmaceuticals LLC | $13.47 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.71 | 2019 | |
| Merck Sharp & Dohme LLC | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Pieniazek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.